Abstract
Background: The objective of this study was to develop and validate a short form of the Patient Health Questionnaire-9 (PHQ-9), a self-report questionnaire for assessing depressive symptomatology, using objective criteria. Methods: Responses on the PHQ-9 were obtained from 7,850 English-speaking participants enrolled in 20 primary diagnostic test accuracy studies. PHQ unidimensionality was verified using confirmatory factor analysis, and an item response theory model was fit. Optimal test assembly (OTA) methods identified a maximally precise short form for each possible length between one and eight items, including and excluding the ninth item. The final short form was selected based on prespecified validity, reliability, and diagnostic accuracy criteria. Results: A four-item short form of the PHQ (PHQ-Dep-4) was selected. The PHQ-Dep-4 had a Cronbach's alpha of 0.805. Sensitivity and specificity of the PHQ-Dep-4 were 0.788 and 0.837, respectively, and were statistically equivalent to the PHQ-9 (sensitivity = 0.761, specificity = 0.866). The correlation of total scores with the full PHQ-9 was high (r = 0.919). Conclusion: The PHQ-Dep-4 is a valid short form with minimal loss of information of scores when compared to the full-length PHQ-9. Although OTA methods have been used to shorten patient-reported outcome measures based on objective, prespecified criteria, further studies are required to validate this general procedure for broader use in health research. Furthermore, due to unexamined heterogeneity, there is a need to replicate the results of this study in different patient populations.
Original language | English |
---|---|
Pages (from-to) | 82-92 |
Number of pages | 11 |
Journal | Depression and Anxiety |
Volume | 36 |
Issue number | 1 |
Early online date | 20 Sept 2018 |
DOIs | |
Publication status | Published - Jan 2019 |
Bibliographical note
FOCUS ON: MEASURING AND DETECTING DEPRESSIONFunding
Funders | Funder number |
---|---|
Australian National Health and Medical Research Council | |
Bay-lor College of Medicine | H133N060003 |
Cure Scleroderma Foundation | |
Department of Education | |
Department of Veterans | |
Euroimmun | |
Inova Diagnostics Inc | |
Inova Diagnostics, Inc. | |
Institute | |
National Health Service Lothian Neuro-Oncology Endowment Fund | |
Scleroderma Society of Canada | |
Scleroderma Society of Saskatchewan | |
Sclérodermie Québec | |
Vanier Canada Graduate Scholarship | |
National Institutes of Health | T32 GM07356 |
U.S. Department of Health and Human Services | |
National Institute of Mental Health | K02 MH65919, R24 MH56858, R34 MH072925, R34MH084673 |
National Institute of Diabetes and Digestive and Kidney Diseases | P30DK050456 |
National Center for Research Resources | TL1 RR024135 |
Health Resources and Services Administration | R40MC07840 |
Agency for Healthcare Research and Quality | R36 HS018246, R24MH071604 |
Robert Wood Johnson Foundation | |
American Federation for Aging Research | |
Pfizer | |
National Institute on Disability and Rehabilitation Research | |
New York University | |
Ischemia Research and Education Foundation | |
University of Michigan | H133N060032 |
Alberta Health Services | |
University of Washington | H133N060033 |
Hotchkiss Brain Institute | |
Canadian Institutes of Health Research | KRS-134297 |
Fonds de Recherche du Québec - Santé | |
National Institute for Health Research | RO1-MH069666, RP-PG-0606-1142, 1088313 |
National Heart and Lung Institute | R01 HL079235 |
Australian Research Council | FT130101444 |
National Health and Medical Research Council | 1002160 |
Hunter Medical Research Institute | |
Health Research Council of New Zealand | FRN 83518 |
Canadian Arthritis Network | |
Lady Davis Institute for Medical Research | |
Scleroderma Society of Ontario |
Keywords
- depression
- Patient Health Questionnaire
- patient outcome assessment
- psychometrics